Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).

In 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. Following the label expansion, Amvuttra became the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone.